ENDURING
-
PEGylated Bispecific ADC Technology
Over the last decade, ADC therapies have demonstrated much improved target selectivity and efficacy when comparing to traditional, nonspecific cytotoxic small molecule drugs, but current ADC technologies are still facing two major problems: very poor tumor penetration and severe toxicity.
Three main factors contribute to the ADC’s toxicity: unstable chemical bonds, Fc mediated toxicity and non-specific internalization.
Enduring LTD has developed several novel PEGylated BsADCs (P-BsADC), by conjugating a fusion protein of two-scFvs, which target at two different epitopes of receptors or two different receptors, with a pegylated cytotoxic payload. P-BsADCs demonstrate much better tumor penetration than IgG based ADC and no Fc mediated toxicity encountered by traditional ADCs.
Our data also shows that P-BsADCs are stable with no detectable release of the payload when incubating with human PBMC for several weeks at 37 oC, have excellent in-vitro cytotoxicity and in-vivo inhibition of xenograft tumor and accelerated internalization without detectable efflux, suggesting improved endosome and lysosome trafficking.
-
PEGylated Bispecific Antibody Technology
A bispecific monoclonal antibody (BsAb) is an artificial protein that comprises antigen-binding fragments of two different monoclonal antibodies. It can bind to two different types of antigen or two different epitopes of the same antigen. The most widely application of this artificial protein is in cancer immunotherapy, where an engineered BsAb binds both to a receptor of cytotoxic cell, e.g., CD3, and a receptor of cancer cell, e.g., CD19, and redirect cytotoxic cell, e.g. T cell, to kill the cancer cells. Unfortunately, clinical studies show that T cell-based bispecific antibodies often exhibit severe cytokine storms, which limit their applications to a few clinical indications.
The unique technology of Dual Site-specific PEGylated Bispecific Antibody (DSP-BsAb) developed by Enduring has the characteristics of safety, selectivity and potency. The PEGylated T cell engager bispecific antibody (P-T-BsAb) developed by Enduring, therefore, could be especially useful to address the cytokine storms resulted from T-cell based bispecific antibody drugs while improving the selectivity of pathological target cells without harming health cells.
-
Company latest research result......
2023-08-03
-
JY201 data were presented firs......
2022-04-14
-
Company completed Series A Fin......
2021-09-18
-
Company move to a new location
2021-07-28
Guangdong public network security 44030902003233(AII Rights Reserved)
Enduring Biotech